You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科興生物(688136.SH)與安泰維生物合作開發抗新冠病毒小分子口服藥
阿思達克 02-21 11:42
科興生物(688136.SH)公布,全資子公司深圳科興藥業於2月18日與深圳安泰維生物簽署協議,合作開發抗新冠病毒小分子口服藥,安泰維將向深圳科興獨佔授權其取得或持有的SHEN26在全球區域的專利、轉讓產品開發和全球商業化的獨家權益,包括現在已有及未來獲得的相關專 利的使用權、產品研究、註冊、臨床和商業化的生產、經銷、推廣的權益。 SHEN26是用於治療新冠及其他病毒感染的抗病毒藥物,已被列入2021年度廣東 省防控新型冠狀病毒感染科技攻關應急專項,目前產品處於臨床前研究階段。 合作費用包括首付款、研發里程碑款合計1億元人民幣,其中首付款2,000萬元人民幣用於項目啟動及取得安泰維10%股權,公司將在獲得中國緊急使用授權或正式批准上市後支付最後一筆研發里程碑款。另外針對SHEN26在全球區域內的年淨銷售額,深圳科興向安泰維支付一定比例的銷售提成費,並在達到一定金額後支付商業化獎勵。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account